Abstract

Few studies have demonstrated gene/environment interactions in cancer research. Using data on high-risk occupations for 2258 case patients and 2410 control patients from two bladder cancer studies, we observed that three of 16 known or candidate bladder cancer susceptibility variants displayed statistically significant and consistent evidence of additive interactions; specifically, the GSTM1 deletion polymorphism (Pinteraction ≤ .001), rs11892031 (UGT1A, Pinteraction = .01), and rs798766 (TMEM129-TACC3-FGFR3, Pinteraction = .03). There was limited evidence for multiplicative interactions. When we examined detailed data on a prevalent occupational exposure associated with increased bladder cancer risk, straight metalworking fluids, we also observed statistically significant additive interaction for rs798766 (TMEM129-TACC3-FGFR3, Pinteraction = .02), with the interaction more apparent in patients with tumors positive for FGFR3 expression. All statistical tests were two-sided. The interaction we observed for rs798766 (TMEM129-TACC3-FGFR3) with specific exposure to straight metalworking fluids illustrates the value of integrating germline genetic variation, environmental exposures, and tumor marker data to provide insight into the mechanisms of bladder carcinogenesis.

Occupational exposures are a leading cause of bladder cancer, second only to smoking (1). Over 40 high-risk occupations for bladder cancer have been identified (1–3), yet few studies have examined whether the occupational risk is modified by genetic factors. We have demonstrated that the effect of smoking on absolute risk of bladder cancer, quantified using risk difference (RD) parameters, can vary by genetic susceptibility loci for bladder cancer (4–5). To further explore gene/environment interactions, we examined whether common single-nucleotide polymorphisms (SNPs) modify the association between employment in high-risk occupations and bladder cancer risk using data from 2258 case patients and 2410 control patients who participated in the New England Bladder Cancer Study (NEBCS) and the Spanish Bladder Cancer Study (6–7). All subjects gave informed consent, and each study was approved by the host institution’s internal review board.

Lifetime occupational histories were obtained and exposure-oriented questionnaire modules were administered to elicit information on selected exposures (2–3). High-risk occupations were identified separately by sex in each study (2–3), defined as those with bladder cancer odds ratios (ORs) of 1.5 or greater and with 10 or more employed individuals (Supplementary Table 1, available online), and were analyzed as a group hypothesizing a common mechanism of action from exposure to a mixture of putative carcinogens. We also assessed interactions with an a priori suspect occupational exposure, straight metalworking fluids (composed of mineral oils plus additives), which is common among the more prevalent high-risk occupations in both New England and Spain (Supplementary Table 1, available online). Based on detailed exposure data to quantify exposure to straight metalworking fluids in the NEBCS, we have shown a statistically significant association with increased bladder cancer risk (8). We used data on 16 SNPs identified as susceptibility variants for bladder cancer (4,9–17) to evaluate multiplicative and additive interactions. The Supplementary Materials (available online) contain additional details on genotyping, genome-wide interaction analysis, and the statistical methods used to assess interaction (5,18). All statistical tests were two-sided, and a P value of less than .05 was considered statistically significant.

For five loci we observed a statistically significant interaction with employment in a high-risk occupation (Pinteraction < .05) (Table 1). Four loci had statistically significant differences in the RD for high-risk occupation by genotype (Padditive interaction < .05) (Table 1), the GSTM1 deletion polymorphism (Pinteraction ≤ .001), rs11892031 (UGT1A, Pinteraction = .01), rs907611 (LSP1- miRNA-4298, Pinteraction = .01), and rs798766 (TMEM129-TACC3-FGFR3, Pinteraction = .03). In sensitivity analyses based on higher odds ratio cutpoints to define high-risk occupation (OR ≥ 1.7 or ≥ 2.0), three of these four SNPs showed consistent evidence for differences in RD for high-risk occupation by genotype, specifically rs11892031 (UGT1A), rs798766 (TMEM129-TACC3-FGFR3), and GSTM1 present/null genotype (Supplementary Table 2, available online). Evidence of additive interactions for rs798766 (TMEM129-TACC3-FGFR3) and GSTM1 present/null genotype were also present when the genotypes were modeled as a three-level categorical variable rather than as a binary variable assuming a dominant model (Supplementary Table 3, available online). The evidence for additive interaction was strongest for GSTM1. We estimated that the difference in the 30-year absolute risk for men age 50 years living in the United States with and without a high-risk occupation was 3.0% for carriers of GSTM1-null and 1.9% GSTM1-present genotypes (Supplementary Table 4, available online) (5,19). There was limited evidence of multiplicative interaction, with only rs401681 (TERT-CPTML) showing statistically significant differences in the relative risk for high-risk occupation by genotype (Pmultiplicative interaction = .03) (Table 1; Supplementary Table 2, available online).

Table 1.

Association between employment in a high-risk occupation and bladder cancer risk by susceptibility allele status in the New England Bladder Cancer Study and the Spanish Bladder Cancer Study

No risk alleleOne or two risk alleles
Gene regionSNPEmployed in a high-risk occupation* (Yes/No)Case patients, No.Control patients, No.OR† (95% CI)PCase patientsControl patientsOR† (95% CI)PP additive interaction‡P multiplicative interaction§
UGT1Ars11892031No170280Ref9791272Ref
Yes117972.14 (1.50 to 3.05)2.76×10-58135182.20 (1.90 to 2.54)2.69×10-26.01.15
TP63rs710521No70123Ref10601397Ref
Yes51432.81 (1.59 to 4.96)3.91×10-48605562.19 (1.90 to 2.52)6.97×10-28.12.61
TMEM129- TACC3-FGFR3rs798766No7211025Ref426530Ref
Yes5654212.09 (1.77 to 2.48)5.31×10-183661962.48 (1.98 to 3.11)4.37×10-15.03.33
TERT-CLPTMLrs401681No185322Ref9491208Ref
Yes1821222.96 (2.16 to 4.06)1.61×10-117294782.09 (1.80 to 2.43)9.81×10-22.39.03
NAT2rs1495741No416631Ref733922Ref
Yes3372582.09 (1.68 to 2.59)2.20×10-115953582.31 (1.94 to 2.74)1.98×10-21.16.99
rs9642880No318470Ref8151057Ref
Yes2482011.96 (1.53 to 2.51)8.59×10-86613982.36 (2.00 to 2.77)7.22×10-25.12.72
PSCArs2294008No311443Ref8361104Ref
Yes2551982.08 (1.62 to 2.67)1.18×10-86764152.32 (1.98 to 2.72)7.58×10-25.57.90
CCNE1rs8102137No476731Ref674822Ref
Yes3932582.52 (2.05 to 3.10)3.24×10-185403592.02 (1.70 to 2.41)5.13×10-15.44.81
CBX6-APOBEC3Ars1014971No98176Ref10521377Ref
Yes76672.46 (1.57 to 3.86)8.74×10-58575502.19 (1.90 to 2.52)1.10×10-27.18.85
UGT1Ars17863783No3979Ref11051473Ref
Yes28281.67 (0.78 to 3.59)1.85×10-19035852.23 (1.95 to 2.56)1.53×10-30.07.60
SLC14A2rs10775480/ rs10853535No319485Ref8271066Ref
Yes2841882.47 (1.93 to 3.16)5.85×10-136474272.16 (1.83 to 2.53)8.46×10-211.00.94
GSTM1null vs presentNo457777Ref735894Ref
Yes3643112.11 (1.72 to 2.58)7.10×10-136243512.36 (1.99 to 2.81)7.66×10-23<.001.42
TERCrs10936599No4478Ref10861443Ref
Yes46312.61 (1.35 to 5.06)4.36×10-38595642.19 (1.91 to 2.52)1.99×10-28.46.20
LSP1- miRNA-4298rs907611No474706Ref643794Ref
Yes3582772.13 (1.73 to 2.63)8.18×10-135333092.31 (1.92 to 2.78)4.37×10-19.01.25
rs6104690No162275Ref9671237Ref
Yes1491042.77 (1.96 to 3.90)6.63×10-97514882.11 (1.82 to 2.45)9.17×10-23.81.19
CDKAL1rs4510656No227318Ref9041204Ref
Yes1761282.21 (1.63 to 2.99)3.23×10-77294672.23 (1.91 to 2.60)6.80×10-25.28.73
No risk alleleOne or two risk alleles
Gene regionSNPEmployed in a high-risk occupation* (Yes/No)Case patients, No.Control patients, No.OR† (95% CI)PCase patientsControl patientsOR† (95% CI)PP additive interaction‡P multiplicative interaction§
UGT1Ars11892031No170280Ref9791272Ref
Yes117972.14 (1.50 to 3.05)2.76×10-58135182.20 (1.90 to 2.54)2.69×10-26.01.15
TP63rs710521No70123Ref10601397Ref
Yes51432.81 (1.59 to 4.96)3.91×10-48605562.19 (1.90 to 2.52)6.97×10-28.12.61
TMEM129- TACC3-FGFR3rs798766No7211025Ref426530Ref
Yes5654212.09 (1.77 to 2.48)5.31×10-183661962.48 (1.98 to 3.11)4.37×10-15.03.33
TERT-CLPTMLrs401681No185322Ref9491208Ref
Yes1821222.96 (2.16 to 4.06)1.61×10-117294782.09 (1.80 to 2.43)9.81×10-22.39.03
NAT2rs1495741No416631Ref733922Ref
Yes3372582.09 (1.68 to 2.59)2.20×10-115953582.31 (1.94 to 2.74)1.98×10-21.16.99
rs9642880No318470Ref8151057Ref
Yes2482011.96 (1.53 to 2.51)8.59×10-86613982.36 (2.00 to 2.77)7.22×10-25.12.72
PSCArs2294008No311443Ref8361104Ref
Yes2551982.08 (1.62 to 2.67)1.18×10-86764152.32 (1.98 to 2.72)7.58×10-25.57.90
CCNE1rs8102137No476731Ref674822Ref
Yes3932582.52 (2.05 to 3.10)3.24×10-185403592.02 (1.70 to 2.41)5.13×10-15.44.81
CBX6-APOBEC3Ars1014971No98176Ref10521377Ref
Yes76672.46 (1.57 to 3.86)8.74×10-58575502.19 (1.90 to 2.52)1.10×10-27.18.85
UGT1Ars17863783No3979Ref11051473Ref
Yes28281.67 (0.78 to 3.59)1.85×10-19035852.23 (1.95 to 2.56)1.53×10-30.07.60
SLC14A2rs10775480/ rs10853535No319485Ref8271066Ref
Yes2841882.47 (1.93 to 3.16)5.85×10-136474272.16 (1.83 to 2.53)8.46×10-211.00.94
GSTM1null vs presentNo457777Ref735894Ref
Yes3643112.11 (1.72 to 2.58)7.10×10-136243512.36 (1.99 to 2.81)7.66×10-23<.001.42
TERCrs10936599No4478Ref10861443Ref
Yes46312.61 (1.35 to 5.06)4.36×10-38595642.19 (1.91 to 2.52)1.99×10-28.46.20
LSP1- miRNA-4298rs907611No474706Ref643794Ref
Yes3582772.13 (1.73 to 2.63)8.18×10-135333092.31 (1.92 to 2.78)4.37×10-19.01.25
rs6104690No162275Ref9671237Ref
Yes1491042.77 (1.96 to 3.90)6.63×10-97514882.11 (1.82 to 2.45)9.17×10-23.81.19
CDKAL1rs4510656No227318Ref9041204Ref
Yes1761282.21 (1.63 to 2.99)3.23×10-77294672.23 (1.91 to 2.60)6.80×10-25.28.73

*A high-risk occupation was defined to include all occupations where the odds ratio was 1.5 or higher and 10 or more individuals were employed. CI = confidence interval; OR = odds ratio; SNP = single-nucleotide polymorphism; Ref = reference.

† Odds ratios are adjusted for smoking status, region/state, age, and sex. All tests for gene/environment interactions were conducted using categorical variables (each single-nucleotide polymorphism was coded as a dichotomous variable indicating the presence or absence of any risk allele).

‡ Test for additive interaction based on likelihood ratio test assuming gene-environment independence; all statistical tests were two-sided.

§ Test for multiplicative interaction based on likelihood ratio test assuming gene-environment independence; all statistical tests were two-sided.

Table 1.

Association between employment in a high-risk occupation and bladder cancer risk by susceptibility allele status in the New England Bladder Cancer Study and the Spanish Bladder Cancer Study

No risk alleleOne or two risk alleles
Gene regionSNPEmployed in a high-risk occupation* (Yes/No)Case patients, No.Control patients, No.OR† (95% CI)PCase patientsControl patientsOR† (95% CI)PP additive interaction‡P multiplicative interaction§
UGT1Ars11892031No170280Ref9791272Ref
Yes117972.14 (1.50 to 3.05)2.76×10-58135182.20 (1.90 to 2.54)2.69×10-26.01.15
TP63rs710521No70123Ref10601397Ref
Yes51432.81 (1.59 to 4.96)3.91×10-48605562.19 (1.90 to 2.52)6.97×10-28.12.61
TMEM129- TACC3-FGFR3rs798766No7211025Ref426530Ref
Yes5654212.09 (1.77 to 2.48)5.31×10-183661962.48 (1.98 to 3.11)4.37×10-15.03.33
TERT-CLPTMLrs401681No185322Ref9491208Ref
Yes1821222.96 (2.16 to 4.06)1.61×10-117294782.09 (1.80 to 2.43)9.81×10-22.39.03
NAT2rs1495741No416631Ref733922Ref
Yes3372582.09 (1.68 to 2.59)2.20×10-115953582.31 (1.94 to 2.74)1.98×10-21.16.99
rs9642880No318470Ref8151057Ref
Yes2482011.96 (1.53 to 2.51)8.59×10-86613982.36 (2.00 to 2.77)7.22×10-25.12.72
PSCArs2294008No311443Ref8361104Ref
Yes2551982.08 (1.62 to 2.67)1.18×10-86764152.32 (1.98 to 2.72)7.58×10-25.57.90
CCNE1rs8102137No476731Ref674822Ref
Yes3932582.52 (2.05 to 3.10)3.24×10-185403592.02 (1.70 to 2.41)5.13×10-15.44.81
CBX6-APOBEC3Ars1014971No98176Ref10521377Ref
Yes76672.46 (1.57 to 3.86)8.74×10-58575502.19 (1.90 to 2.52)1.10×10-27.18.85
UGT1Ars17863783No3979Ref11051473Ref
Yes28281.67 (0.78 to 3.59)1.85×10-19035852.23 (1.95 to 2.56)1.53×10-30.07.60
SLC14A2rs10775480/ rs10853535No319485Ref8271066Ref
Yes2841882.47 (1.93 to 3.16)5.85×10-136474272.16 (1.83 to 2.53)8.46×10-211.00.94
GSTM1null vs presentNo457777Ref735894Ref
Yes3643112.11 (1.72 to 2.58)7.10×10-136243512.36 (1.99 to 2.81)7.66×10-23<.001.42
TERCrs10936599No4478Ref10861443Ref
Yes46312.61 (1.35 to 5.06)4.36×10-38595642.19 (1.91 to 2.52)1.99×10-28.46.20
LSP1- miRNA-4298rs907611No474706Ref643794Ref
Yes3582772.13 (1.73 to 2.63)8.18×10-135333092.31 (1.92 to 2.78)4.37×10-19.01.25
rs6104690No162275Ref9671237Ref
Yes1491042.77 (1.96 to 3.90)6.63×10-97514882.11 (1.82 to 2.45)9.17×10-23.81.19
CDKAL1rs4510656No227318Ref9041204Ref
Yes1761282.21 (1.63 to 2.99)3.23×10-77294672.23 (1.91 to 2.60)6.80×10-25.28.73
No risk alleleOne or two risk alleles
Gene regionSNPEmployed in a high-risk occupation* (Yes/No)Case patients, No.Control patients, No.OR† (95% CI)PCase patientsControl patientsOR† (95% CI)PP additive interaction‡P multiplicative interaction§
UGT1Ars11892031No170280Ref9791272Ref
Yes117972.14 (1.50 to 3.05)2.76×10-58135182.20 (1.90 to 2.54)2.69×10-26.01.15
TP63rs710521No70123Ref10601397Ref
Yes51432.81 (1.59 to 4.96)3.91×10-48605562.19 (1.90 to 2.52)6.97×10-28.12.61
TMEM129- TACC3-FGFR3rs798766No7211025Ref426530Ref
Yes5654212.09 (1.77 to 2.48)5.31×10-183661962.48 (1.98 to 3.11)4.37×10-15.03.33
TERT-CLPTMLrs401681No185322Ref9491208Ref
Yes1821222.96 (2.16 to 4.06)1.61×10-117294782.09 (1.80 to 2.43)9.81×10-22.39.03
NAT2rs1495741No416631Ref733922Ref
Yes3372582.09 (1.68 to 2.59)2.20×10-115953582.31 (1.94 to 2.74)1.98×10-21.16.99
rs9642880No318470Ref8151057Ref
Yes2482011.96 (1.53 to 2.51)8.59×10-86613982.36 (2.00 to 2.77)7.22×10-25.12.72
PSCArs2294008No311443Ref8361104Ref
Yes2551982.08 (1.62 to 2.67)1.18×10-86764152.32 (1.98 to 2.72)7.58×10-25.57.90
CCNE1rs8102137No476731Ref674822Ref
Yes3932582.52 (2.05 to 3.10)3.24×10-185403592.02 (1.70 to 2.41)5.13×10-15.44.81
CBX6-APOBEC3Ars1014971No98176Ref10521377Ref
Yes76672.46 (1.57 to 3.86)8.74×10-58575502.19 (1.90 to 2.52)1.10×10-27.18.85
UGT1Ars17863783No3979Ref11051473Ref
Yes28281.67 (0.78 to 3.59)1.85×10-19035852.23 (1.95 to 2.56)1.53×10-30.07.60
SLC14A2rs10775480/ rs10853535No319485Ref8271066Ref
Yes2841882.47 (1.93 to 3.16)5.85×10-136474272.16 (1.83 to 2.53)8.46×10-211.00.94
GSTM1null vs presentNo457777Ref735894Ref
Yes3643112.11 (1.72 to 2.58)7.10×10-136243512.36 (1.99 to 2.81)7.66×10-23<.001.42
TERCrs10936599No4478Ref10861443Ref
Yes46312.61 (1.35 to 5.06)4.36×10-38595642.19 (1.91 to 2.52)1.99×10-28.46.20
LSP1- miRNA-4298rs907611No474706Ref643794Ref
Yes3582772.13 (1.73 to 2.63)8.18×10-135333092.31 (1.92 to 2.78)4.37×10-19.01.25
rs6104690No162275Ref9671237Ref
Yes1491042.77 (1.96 to 3.90)6.63×10-97514882.11 (1.82 to 2.45)9.17×10-23.81.19
CDKAL1rs4510656No227318Ref9041204Ref
Yes1761282.21 (1.63 to 2.99)3.23×10-77294672.23 (1.91 to 2.60)6.80×10-25.28.73

*A high-risk occupation was defined to include all occupations where the odds ratio was 1.5 or higher and 10 or more individuals were employed. CI = confidence interval; OR = odds ratio; SNP = single-nucleotide polymorphism; Ref = reference.

† Odds ratios are adjusted for smoking status, region/state, age, and sex. All tests for gene/environment interactions were conducted using categorical variables (each single-nucleotide polymorphism was coded as a dichotomous variable indicating the presence or absence of any risk allele).

‡ Test for additive interaction based on likelihood ratio test assuming gene-environment independence; all statistical tests were two-sided.

§ Test for multiplicative interaction based on likelihood ratio test assuming gene-environment independence; all statistical tests were two-sided.

Recognizing that employment in high-risk occupations reflects heterogeneous exposures, we further explored interactions using detailed data on a specific exposure, straight metalworking fluids. We observed statistically significant differences in the RD for straight metalworking fluids by rs798766 genotype (Padditive interaction = .02) (Table 2; Supplementary Table 4, available online).

Table 2.

Association between straight metalworking fluids exposure and bladder cancer risk by susceptibility alleles in the New England Bladder Cancer Study

No risk alleleOne or two risk alleles
Gene regionSNPDirect/probable straight metalworking fluids exposure (Yes/No)Case patientsControl patientsOR* (95% CI)PCase patientsControl patientsOR* (95% CI)PP additive interaction†‡P multiplicative interaction§
UGT1Ars11892031No3246Ref190258Ref
Yes843.86 (0.89 to 16.85).07244331.77 (1.06 to 2.94).028-†-†
TP63rs710521No715Ref213275Ref
Yes121.92 (0.04 to 94.7).74247331.85 1.12 to 3.05).017-†-†
TMEM129-TACC3-FGFR3rs798766No141202Ref84103Ref
Yes25261.44 (0.77 to 2.7).25227113.25(1.45 to 7.27).004.02.06
TERT-CLPTMLrs401681No3061Ref191235Ref
Yes1274.11 (1.22 to 13.85).02236281.62 (0.93 to 2.83).089.19.06
NAT2rs1495741No83118Ref142185Ref
Yes23171.86 (0.9 to 3.86).09328201.84 (0.96 to 3.50).064.33.28
rs9642880No7094Ref149198Ref
Yes15141.11 (0.48 to 2.58).80233212.33 (1.24 to 4.36).008.84.92
PSCArs2294008No5798Ref168206Ref
Yes1492.66 (1.01 to 6.96).04738281.65 (0.95 to 2.87).078.88.81
CCNE1rs8102137No95131Ref130174Ref
Yes20141.68 (0.77 to 3.67).19132231.98 (1.07 to 3.68).031.62.62
CBX6-APOBEC3Ars1014971No2141Ref204263Ref
Yes390.65 (0.12 to 3.36).60349282.17 (1.29 to 3.67).004-†-†
UGT1Ars17863783No614Ref218291Ref
Yes237.93 (0.17 to 377.01).29350341.92 (1.18 to 3.13).009-†-†
SLC14A2rs10775480/ rs10853535No6690Ref159214Ref
Yes1462.92 (1 to 8.51).05038311.62 (0.94 to 2.79).080.89.78
GSTM1null vs presentNo83133Ref151182Ref
Yes21231.50 (0.75 to 3.01).24835211.96 (1.07 to 3.62).031.79.78
TERCrs10936599No1113Ref207280Ref
Yes230.43 (0.04 to 4.81).49646321.97 (1.18 to 3.27).009-†-†
LSP1- miRNA-4298rs907611No88131Ref127154Ref
Yes25162.40 (1.15 to 5.04).02022181.47 (0.73 to 2.96).276.15.91
rs6104690No4055Ref176235Ref
Yes370.76 (0.16 to 3.69).73444272.16 (1.26 to 3.70).005-†-†
CDKAL1rs4510656No4061Ref179232Ref
Yes853.61 (0.95 to 13.8).06040301.70 (0.99 to 2.91).055.72.79
No risk alleleOne or two risk alleles
Gene regionSNPDirect/probable straight metalworking fluids exposure (Yes/No)Case patientsControl patientsOR* (95% CI)PCase patientsControl patientsOR* (95% CI)PP additive interaction†‡P multiplicative interaction§
UGT1Ars11892031No3246Ref190258Ref
Yes843.86 (0.89 to 16.85).07244331.77 (1.06 to 2.94).028-†-†
TP63rs710521No715Ref213275Ref
Yes121.92 (0.04 to 94.7).74247331.85 1.12 to 3.05).017-†-†
TMEM129-TACC3-FGFR3rs798766No141202Ref84103Ref
Yes25261.44 (0.77 to 2.7).25227113.25(1.45 to 7.27).004.02.06
TERT-CLPTMLrs401681No3061Ref191235Ref
Yes1274.11 (1.22 to 13.85).02236281.62 (0.93 to 2.83).089.19.06
NAT2rs1495741No83118Ref142185Ref
Yes23171.86 (0.9 to 3.86).09328201.84 (0.96 to 3.50).064.33.28
rs9642880No7094Ref149198Ref
Yes15141.11 (0.48 to 2.58).80233212.33 (1.24 to 4.36).008.84.92
PSCArs2294008No5798Ref168206Ref
Yes1492.66 (1.01 to 6.96).04738281.65 (0.95 to 2.87).078.88.81
CCNE1rs8102137No95131Ref130174Ref
Yes20141.68 (0.77 to 3.67).19132231.98 (1.07 to 3.68).031.62.62
CBX6-APOBEC3Ars1014971No2141Ref204263Ref
Yes390.65 (0.12 to 3.36).60349282.17 (1.29 to 3.67).004-†-†
UGT1Ars17863783No614Ref218291Ref
Yes237.93 (0.17 to 377.01).29350341.92 (1.18 to 3.13).009-†-†
SLC14A2rs10775480/ rs10853535No6690Ref159214Ref
Yes1462.92 (1 to 8.51).05038311.62 (0.94 to 2.79).080.89.78
GSTM1null vs presentNo83133Ref151182Ref
Yes21231.50 (0.75 to 3.01).24835211.96 (1.07 to 3.62).031.79.78
TERCrs10936599No1113Ref207280Ref
Yes230.43 (0.04 to 4.81).49646321.97 (1.18 to 3.27).009-†-†
LSP1- miRNA-4298rs907611No88131Ref127154Ref
Yes25162.40 (1.15 to 5.04).02022181.47 (0.73 to 2.96).276.15.91
rs6104690No4055Ref176235Ref
Yes370.76 (0.16 to 3.69).73444272.16 (1.26 to 3.70).005-†-†
CDKAL1rs4510656No4061Ref179232Ref
Yes853.61 (0.95 to 13.8).06040301.70 (0.99 to 2.91).055.72.79

* Odds ratios are adjusted for smoking status, region/state, age, and sex. All tests for gene/environment interactions were conducted using categorical variables (each single-nucleotide polymorphism was coded as a dichotomous variable indicating the presence or absence of any risk allele). CI = confidence interval; OR = odds ratio; SNP = single-nucleotide polymorphism; Ref = reference.

† Interaction P values were not calculated for rs11892031, rs710521, rs1014971, rs17863783, rs10936599, and rs6104690 because of cell counts containing fewer than five subjects.

‡ Test for additive interaction based on likelihood ratio test assuming gene-environment independence; all statistical tests were two-sided.

§ Test for multiplicative interaction based on likelihood ratio test assuming gene-environment independence; all statistical tests were two-sided.

Table 2.

Association between straight metalworking fluids exposure and bladder cancer risk by susceptibility alleles in the New England Bladder Cancer Study

No risk alleleOne or two risk alleles
Gene regionSNPDirect/probable straight metalworking fluids exposure (Yes/No)Case patientsControl patientsOR* (95% CI)PCase patientsControl patientsOR* (95% CI)PP additive interaction†‡P multiplicative interaction§
UGT1Ars11892031No3246Ref190258Ref
Yes843.86 (0.89 to 16.85).07244331.77 (1.06 to 2.94).028-†-†
TP63rs710521No715Ref213275Ref
Yes121.92 (0.04 to 94.7).74247331.85 1.12 to 3.05).017-†-†
TMEM129-TACC3-FGFR3rs798766No141202Ref84103Ref
Yes25261.44 (0.77 to 2.7).25227113.25(1.45 to 7.27).004.02.06
TERT-CLPTMLrs401681No3061Ref191235Ref
Yes1274.11 (1.22 to 13.85).02236281.62 (0.93 to 2.83).089.19.06
NAT2rs1495741No83118Ref142185Ref
Yes23171.86 (0.9 to 3.86).09328201.84 (0.96 to 3.50).064.33.28
rs9642880No7094Ref149198Ref
Yes15141.11 (0.48 to 2.58).80233212.33 (1.24 to 4.36).008.84.92
PSCArs2294008No5798Ref168206Ref
Yes1492.66 (1.01 to 6.96).04738281.65 (0.95 to 2.87).078.88.81
CCNE1rs8102137No95131Ref130174Ref
Yes20141.68 (0.77 to 3.67).19132231.98 (1.07 to 3.68).031.62.62
CBX6-APOBEC3Ars1014971No2141Ref204263Ref
Yes390.65 (0.12 to 3.36).60349282.17 (1.29 to 3.67).004-†-†
UGT1Ars17863783No614Ref218291Ref
Yes237.93 (0.17 to 377.01).29350341.92 (1.18 to 3.13).009-†-†
SLC14A2rs10775480/ rs10853535No6690Ref159214Ref
Yes1462.92 (1 to 8.51).05038311.62 (0.94 to 2.79).080.89.78
GSTM1null vs presentNo83133Ref151182Ref
Yes21231.50 (0.75 to 3.01).24835211.96 (1.07 to 3.62).031.79.78
TERCrs10936599No1113Ref207280Ref
Yes230.43 (0.04 to 4.81).49646321.97 (1.18 to 3.27).009-†-†
LSP1- miRNA-4298rs907611No88131Ref127154Ref
Yes25162.40 (1.15 to 5.04).02022181.47 (0.73 to 2.96).276.15.91
rs6104690No4055Ref176235Ref
Yes370.76 (0.16 to 3.69).73444272.16 (1.26 to 3.70).005-†-†
CDKAL1rs4510656No4061Ref179232Ref
Yes853.61 (0.95 to 13.8).06040301.70 (0.99 to 2.91).055.72.79
No risk alleleOne or two risk alleles
Gene regionSNPDirect/probable straight metalworking fluids exposure (Yes/No)Case patientsControl patientsOR* (95% CI)PCase patientsControl patientsOR* (95% CI)PP additive interaction†‡P multiplicative interaction§
UGT1Ars11892031No3246Ref190258Ref
Yes843.86 (0.89 to 16.85).07244331.77 (1.06 to 2.94).028-†-†
TP63rs710521No715Ref213275Ref
Yes121.92 (0.04 to 94.7).74247331.85 1.12 to 3.05).017-†-†
TMEM129-TACC3-FGFR3rs798766No141202Ref84103Ref
Yes25261.44 (0.77 to 2.7).25227113.25(1.45 to 7.27).004.02.06
TERT-CLPTMLrs401681No3061Ref191235Ref
Yes1274.11 (1.22 to 13.85).02236281.62 (0.93 to 2.83).089.19.06
NAT2rs1495741No83118Ref142185Ref
Yes23171.86 (0.9 to 3.86).09328201.84 (0.96 to 3.50).064.33.28
rs9642880No7094Ref149198Ref
Yes15141.11 (0.48 to 2.58).80233212.33 (1.24 to 4.36).008.84.92
PSCArs2294008No5798Ref168206Ref
Yes1492.66 (1.01 to 6.96).04738281.65 (0.95 to 2.87).078.88.81
CCNE1rs8102137No95131Ref130174Ref
Yes20141.68 (0.77 to 3.67).19132231.98 (1.07 to 3.68).031.62.62
CBX6-APOBEC3Ars1014971No2141Ref204263Ref
Yes390.65 (0.12 to 3.36).60349282.17 (1.29 to 3.67).004-†-†
UGT1Ars17863783No614Ref218291Ref
Yes237.93 (0.17 to 377.01).29350341.92 (1.18 to 3.13).009-†-†
SLC14A2rs10775480/ rs10853535No6690Ref159214Ref
Yes1462.92 (1 to 8.51).05038311.62 (0.94 to 2.79).080.89.78
GSTM1null vs presentNo83133Ref151182Ref
Yes21231.50 (0.75 to 3.01).24835211.96 (1.07 to 3.62).031.79.78
TERCrs10936599No1113Ref207280Ref
Yes230.43 (0.04 to 4.81).49646321.97 (1.18 to 3.27).009-†-†
LSP1- miRNA-4298rs907611No88131Ref127154Ref
Yes25162.40 (1.15 to 5.04).02022181.47 (0.73 to 2.96).276.15.91
rs6104690No4055Ref176235Ref
Yes370.76 (0.16 to 3.69).73444272.16 (1.26 to 3.70).005-†-†
CDKAL1rs4510656No4061Ref179232Ref
Yes853.61 (0.95 to 13.8).06040301.70 (0.99 to 2.91).055.72.79

* Odds ratios are adjusted for smoking status, region/state, age, and sex. All tests for gene/environment interactions were conducted using categorical variables (each single-nucleotide polymorphism was coded as a dichotomous variable indicating the presence or absence of any risk allele). CI = confidence interval; OR = odds ratio; SNP = single-nucleotide polymorphism; Ref = reference.

† Interaction P values were not calculated for rs11892031, rs710521, rs1014971, rs17863783, rs10936599, and rs6104690 because of cell counts containing fewer than five subjects.

‡ Test for additive interaction based on likelihood ratio test assuming gene-environment independence; all statistical tests were two-sided.

§ Test for multiplicative interaction based on likelihood ratio test assuming gene-environment independence; all statistical tests were two-sided.

Because rs798766 is located within the FGFR3 region and somatic changes in FGFR3 have been described in bladder tumors, we explored the relationship between tumor FGFR3 expression, the rs798766 genotypes, and straight metalworking fluids exposure (see the Supplementary Material, available online). Using FGFR3 immunohistochemistry data on 483 tumors from New England, we observed a statistically significant association between increased FGFR3 expression and the rs798766 risk allele (P = .01) (see the Supplementary Materials and Supplementary Figures 1–3, available online), consistent with a previous report (10). Data on mRNA expression from 197 bladder tumors also showed a trend of higher levels of FGFR3 expression with the rs798766 risk allele (Supplementary Figure 4, available online). Interestingly, the interaction between straight metalworking fluids and rs798766 was more apparent in the subset of patients with tumors displaying strong/intermediate FGFR3 expression (Padditive interaction = .02) compared with those with weak/no FGFR3 expression (Padditive interaction = .80) (Supplementary Table 5, available online). We found no association between the rs798766 and exposure to straight metalworking fluids in control patients, confirming that these factors are independent. Cumulatively, these data provide support that FGFR3 expression may play a role in defining the underlying mechanistic interaction between the rs798766 and straight metalworking fluid exposure.

It is of interest to note that the three polymorphisms with consistent statistically significant additive interactions with high-risk occupation (GSTM1 null, rs11892031 [UGT1A], rs798766 [TMEM129-TACC3-FGFR3]) have also been observed to have statistically significant additive interactions with exposure to tobacco smoke (4,5,20). Given that GSTM1 and UGT1A are known carcinogen-metabolizing genes, our findings suggest that these genes may be important in the detoxification of one or more bladder chemical carcinogens in both tobacco and some high-risk occupations. Interestingly, a German study also found evidence of interaction among case patients who were both carriers of the GSTM1-null genotype and were employed in occupations exposed to known bladder carcinogens (21,22). Further, we present evidence linking exposure to straight metalworking fluids with bladder cancer risk using FGFR3 tumor expression data. Given that rs798766 also interacts with tobacco smoke (4), these data support the hypothesis that there may be pathways that are common to genotoxic exposures in tobacco smoke and straight metalworking fluids. Lastly, our data support the rs798766 (TMEM129-TACC3-FGFR3) results to be a biologically plausible interaction and also add to the weight of the evidence linking exposure to straight metalworking fluids to bladder cancer risk.

Strengths of our study include high-quality detailed occupational exposure data in two large, well-designed case-control studies. Limitations of our study include limited power to broadly explore gene/environment interactions using the entire genome-wide association study data. Larger studies are needed to replicate and extend the observed findings. Only the P value of less than .001 for the additive interaction test of GSTM1and high-risk occupation remained statistically significant after Bonferroni correction; however, our study revealed additional loci with suggestive interactions with high-risk occupation (eg, UGT1A and LSP1) that will require further study. In addition, although we were able to follow up on our observation of gene/environment interactions with high-risk occupation to a specific prevalent occupational exposure, straight metalworking fluids, we were unable to explore interactions with less prevalent exposures in our study populations because of small numbers of exposed subjects.

In summary, our study provides evidence of gene/environment interactions for occupational exposures and susceptibility loci for bladder cancer. In particular, the interaction we observed for rs798766 (TMEM129-TACC3-FGFR3) with specific exposure to straight metalworking fluids illustrates the value of integrating germline genetic variation, environmental exposures, and tumor marker data to provide insight into the mechanisms of bladder carcinogenesis.

Funding

This work was supported by the Intramural Research Program of the National Institutes of Health and the Division of Cancer Epidemiology and Genetics, National Cancer Institute.

The funders did not play a role in the study design, data collection analysis, writing, or submission of the manuscript.

References

1.

Silverman
DT
Devessa
SS
Moore
L
et al. 
Bladder Cancer
. In:
Fraumeni
JF
Jr.
and
Schottenfeld
D
, (ed).
Cancer Epidemiology and Prevention Third Edition
.
Third Edition ed
.
New York, NY
:
Oxford University Press
;
2006
,
1101
1127
.

2.

Colt
JS
Karagas
MR
Schwenn
M
et al. 
Occupation and bladder cancer in a population-based case-control study in Northern New England
.
Occup Environ Med
.
2011
;
68
(4)
:
239
249
.

3.

Samanic
CM
Kogevinas
M
Silverman
DT
et al. 
Occupation and bladder cancer in a hospital-based case-control study in Spain
.
Occup Environ Med
.
2008
;
65
(5)
:
347
353
.

4.

Figueroa
JD
Ye
Y
Siddiq
A
et al. 
Genome-wide association study identifies multiple loci associated with bladder cancer risk
.
Hum Mol Genet
.
2014
;
23
(5)
:
1387
1398
.

5.

Garcia-Closas
M
Rothman
N
Figueroa
JD
et al. 
Common Genetic Polymorphisms Modify the Effect of Smoking on Absolute Risk of Bladder Cancer
.
Cancer Res
.
2013
;
73
(7)
:
2211
2220
.

6.

Baris
D
Karagas
MR
Verrill
C
et al. 
A case-control study of smoking and bladder cancer risk: emergent patterns over time
.
J Natl Cancer Inst
.
2009
;
101
(22)
:
1553
1561
.

7.

Garcia-Closas
M
Malats
N
Silverman
D
et al. 
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses
.
Lancet
.
2005
;
366
(9486)
:
649
659
.

8.

Colt
JS
Friesen
MC
Stewart
P
et al. 
A Case-Control Study of Occupational Exposure to Metalworking Fluids and Bladder Cancer Risk
.
Occup Environ Med
.
2014
;
71
:
667
674
.

9.

Garcia-Closas
M
Ye
Y
Rothman
N
et al. 
A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3
.
Hum Mol Genet
.
2011
;
20
(21)
:
4282
4289
.

10.

Kiemeney
LA
Sulem
P
Besenbacher
S
et al. 
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer
.
Nat Genet
.
2010
;
42
(5)
:
415
419
.

11.

Kiemeney
LA
Thorlacius
S
Sulem
P
et al. 
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer
.
Nat Genet
.
2008
;
40
(11)
:
1307
1312
.

12.

Rafnar
T
Sulem
P
Stacey
SN
et al. 
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types
.
Nat Genet
.
2009
;
41
(2)
:
221
227
.

13.

Rafnar
T
Vermeulen
SH
Sulem
P
et al. 
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene
.
Hum Mol Genet
.
2011
;
20
(21)
:
4268
4281
.

14.

Rothman
N
Garcia-Closas
M
Chatterjee
N
et al. 
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci
.
Nat Genet
.
2010
;
42
(11)
:
978
984
.

15.

Tang
W
Fu
YP
Figueroa
JD
et al. 
Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer
.
Hum Mol Genet
.
2012
;
21
(8)
:
1918
1930
.

16.

Wu
X
Ye
Y
Kiemeney
LA
et al. 
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer
.
Nat Genet
.
2009
;
41
(9)
:
991
995
.

17.

Garcia-Closas
M
Hein
DW
Silverman
D
et al. 
A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background
.
Pharmacogenet Genomics
.
2011
;
21
(4)
:
231
236
.

18.

Han
SS
Rosenberg
PS
Garcia-Closas
M
et al. 
Likelihood ratio test for detecting gene (G)-environment (E) interactions under an additive risk model exploiting G-E independence for case-control data
.
Am J Epidemiol
.
2012
;
176
(11)
:
1060
1067
.

19.

Petracci
E
Decarli
A
Schairer
C
et al. 
Risk factor modification and projections of absolute breast cancer risk
.
J Natl Cancer Inst
.
2011
;
103
(13)
:
1037
1048
.

20.

Engel
LS
Taioli
E
Pfeiffer
R
et al. 
Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review
.
Am J Epidemiol
.
2002
;
156
(2)
:
95
109
.

21.

Golka
K
Reckwitz
T
Kempkes
M
et al. 
N-Acetyltransferase 2 (NAT2) and Glutathione S-Transferase micro (GSTM1) in Bladder-cancer Patients in a Highly Industrialized Area
.
Int J Occup Environ Health
1997
;
3
(2)
:
105
110
.

22.

Golka
K
Hermes
M
Selinski
S
et al. 
Susceptibility to urinary bladder cancer: relevance of rs9642880[T], GSTM1 0/0 and occupational exposure
.
Pharmacogenet Genomics
2009
;
19
(11)
:
903
6
.

Supplementary data